Next Article in Journal
Cure and Curse: E. coli Heat-Stable Enterotoxin and Its Receptor Guanylyl Cyclase C
Next Article in Special Issue
SLT-VEGF Reduces Lung Metastases, Decreases Tumor Recurrence, and Improves Survival in an Orthotopic Melanoma Model
Previous Article in Journal
Staphylococcal Enterotoxins
Article Menu

Export Article

Open AccessArticle
Toxins 2010, 2(8), 2198-2212; doi:10.3390/toxins2082198

Characterization of SNARE Cleavage Products Generated by Formulated Botulinum Neurotoxin Type-A Drug Products

Allergan, Inc., 2525 Dupont Dr, Irvine, CA 92612, USA
*
Author to whom correspondence should be addressed.
Received: 9 July 2010 / Revised: 10 July 2010 / Accepted: 18 August 2010 / Published: 19 August 2010
(This article belongs to the Special Issue Toxins as Therapeutics)
View Full-Text   |   Download PDF [179 KB, uploaded 19 August 2010]   |  

Abstract

The study evaluated substrate cleavage product(s) generated by three botulinum neurotoxin serotype A (BoNT/A) medicinal drug products utilizing a novel and highly specific, light-chain activity, high-performance liquid chromatography (LCA-HPLC) method. Samples were reacted with a commercially available BoNT/A fluorescent substrate derived from the SNAP-25 sequence. Reaction products were separated by reversed-phase HPLC. The method detected an atypical cleavage pattern by one of the formulated drug products. IncobotulinumtoxinA produced two cleavage fragments rather than the single fragment typically generated by BoNT/A. Identification confirmed the secondary cleavage at a position corresponding to SNAP-25 Arg198–Ala199 (normal BoNT/A cleavage is Gln197–Arg198). Arg198–Ala199 is also the cleavage site for trypsin and serotype C toxin. Normal cleavage was observed for all other BoNT/A drug product samples, as well as 900-kD and 150-kD bulk toxin BoNT/A. The reason for this unexpected secondary cleavage pattern by one formulated BoNT/A drug product is unknown. Possible explanations include a contaminating protease and/or damage to the 150-kD type-A toxin causing nonspecific substrate recognition and subsequent cleavage uncharacteristic of type-A toxin. The BoNT/A drug products were also analyzed via the LCA-HPLC assay using a commercial BoNT/C fluorescent substrate derived from the syntaxin sequence. Cleavage of the serotype C substrate by incobotulinumtoxinA was also confirmed whilst neither of the other drug products cleaved the syntaxin substrate.
Keywords: abotulinumtoxinA; botulinum toxin; BOTOX®; Dysport®; incobotulinumtoxinA; onabotulinumtoxin A; SNAP-25; SNARE; syntaxin; Xeomin® abotulinumtoxinA; botulinum toxin; BOTOX®; Dysport®; incobotulinumtoxinA; onabotulinumtoxin A; SNAP-25; SNARE; syntaxin; Xeomin®
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Hunt, T.; Rupp, D.; Shimizu, G.; Tam, K.; Weidler, J.; Xie, J. Characterization of SNARE Cleavage Products Generated by Formulated Botulinum Neurotoxin Type-A Drug Products. Toxins 2010, 2, 2198-2212.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top